Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM51MSD)

• Drug Name: BPX-101 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DM51MSD

Molecule-Related Drug Atlas

Drug(s) Targeting TNF related activation protein (CD40LG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IL-2/CD40L-expressing leukemia vaccine	DMIHQ5G	Chronic lymphocytic leukaemia	2A82.0	Phase 2	[3]
BI 655064	DMF86P2	Lupus	4A40	Phase 2	[4]
Lucatumumab	DMY2L7V	Lymphoma	2A80-2A86	Phase 2	[5]
Dapirolizumab pegol	DMIYFWA	Systemic lupus erythematosus	4A40.0	Phase 2	[6]
PG-102	DMF5YEN	Autoimmune diabetes	5A10	Phase 2	[7]
ISF35	DMBZK3P	Chronic lymphocytic leukaemia	2A82.0	Phase 2	[8]
CDP-7657	DMN8I5Q	Systemic lupus erythematosus	4A40.0	Phase 1	[9]
MEDI4920	DME7BMT	Rheumatoid arthritis	FA20	Phase 1	[10]
UltraCD40L	DMHG7DZ	Systemic lupus erythematosus	4A40.0	Phase 1	[11]
Chi Lob 7/4	DMSOB5D	B-cell lymphoma	2A86	Phase 1	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
TNF related activation protein (CD40LG)	TTIJP3Q	CD40L_HUMAN	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT00868595) MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer. U.S. National Institutes of Health.
• [2] Activation of antigen-exposed iMC-DCs at the ight place and ight time promotes potent anti-tumor immunity. Oncoimmunology. 2012 May 1; 1(3): 362-363.
• [3] Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and a... Blood. 2006 Feb 15;107(4):1332-41.
• [4] FRI0167 Patient-Reported Outcomes (PROS) During Treatment with Mavrilimumab, A Fully Human Monoclonal Antibody Targeting GMCSFR-Alpha, In the Phase IIB Earth Explorer 1 Study
• [5] Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia.Leuk Lymphoma.2012 Nov;53(11):2136-42.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Induction of an altered CD40 signaling complex by an antagonistic human monoclonal antibody to CD40.J Immunol.2015 May 1;194(9):4319-27.
• [8] Intratumoral injection of Ad-ISF35 (Chimeric CD154) breaks tolerance and induces lymphoma tumor regression. Hum Gene Ther. 2015 Jan;26(1):14-25.
• [9] CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study. Arthritis Res Ther. 2015 Sep 3;17:234.
• [10] ClinicalTrials.gov (NCT02151110) A Phase 1, Randomized, Blinded, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety and Tolerability of MEDI4920 in Healthy Adults. U.S. National Institutes of Health.
• [11] CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells. Cancer Immunol Immunother. 2013 February; 62(2): 347-357.
• [12] Agonistic CD40 antibodies and cancer therapy